Spectrum Pharmaceuticals outlines five-year vision

Spectrum announces new arrival plus its plan for the next five years.

Biotechnical development company Spectrum has announced its five-year plan for advanced growth and market penetration, with its primary focus on haematology and oncology.

The company announced its ambitions while welcoming its new senior vice-president and chief commercial officer Mr Joseph Turgeon, who brings with him 25 years of experience in the pharmaceutical industry.
"Spectrum is committed to continued strong growth over the next five years, with three anticancer drugs on the market and nearly ten drugs in clinical development," said Dr. Shrotriya of Spectrum.
He added that the addition of Mr Turgeon reflected the company's excitement for whatever challenges the new year might bring.

Further expansion of the business is also anticipated, with the strengthening of its sales force expected to allow the firm to increase its presence in six geographic regions across the US.

The realignment of existing resources is also expected to allow physicians a greater level of efficiency.